BCR and diffuse large B-cell lymphoma: PIM1, MYD88, and CD79B mutations are frequent mutations related to MYD88 genetic subtype and activated B cell-like DLBCL dependent on BCR signaling and constitutive activation of NF-κB pathway, which were found to be enriched in patients that experienced inferior survival and early progression upon R-CHOP treatment (23–26).